Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study

Authors: Marya D Zilberberg, Marin H Kollef, Heather Arnold, Andrew Labelle, Scott T Micek, Smita Kothari, Andrew F Shorr

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Candida represents the most common cause of invasive fungal disease, and candidal blood stream infections (CBSI) are prevalent in the ICU. Inappropriate antifungal therapy (IAT) is known to increase a patient's risk for death. We hypothesized that in an ICU cohort it would also adversely affect resource utilization.

Methods

We retrospectively identified all patients with candidemia on or before hospital day 14 and requiring an ICU stay at Barnes-Jewish Hospital between 2004 and 2007. Hospital length of stay following culture-proven onset of CBSI (post-CBSI HLOS) was primary and hospital costs secondary endpoints. IAT was defined as treatment delay of ≥24 hours from candidemia onset or inadequate dose of antifungal agent active against the pathogen. We developed generalized linear models (GLM) to assess independent impact of inappropriate therapy on LOS and costs.

Results

Ninety patients met inclusion criteria. IAT was frequent (88.9%). In the IAT group antifungal delay ≥24 hours occurred in 95.0% and inappropriate dosage in 26.3%. Unadjusted hospital mortality was greater among IAT (28.8%) than non-IAT (0%) patients, p = 0.059. Both crude post-CBSI HLOS (18.4 ± 17.0 vs. 10.7 ± 9.4, p = 0.062) and total costs ($66,584 ± $49,120 vs. $33,526 ± $27,244, p = 0.006) were higher in IAT than in non-IAT. In GLMs adjusting for confounders IAT-attributable excess post-CBSI HLOS was 7.7 days (95% CI 0.6-13.5) and attributable total costs were $13,398 (95% CI $1,060-$26,736).

Conclusions

IAT of CBSI, such as delays and incorrect dosing, occurs commonly. In addition to its adverse impact on clinical outcomes, IAT results in substantial prolongation of hospital LOS and increase in hospital costs. Efforts to enhance rates of appropriate therapy for candidemia may improve resource use.
Literature
1.
go back to reference Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007, 20: 133-63. 10.1128/CMR.00029-06.CrossRefPubMedPubMedCentral Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007, 20: 133-63. 10.1128/CMR.00029-06.CrossRefPubMedPubMedCentral
2.
go back to reference Zilberberg MD, Shorr AF, Kollef MH: Secular trends in candidemia-related hospitalizations in the US, 2000-2005. Infect Control Hosp Epidemiol. 2008, 29: 978-80. 10.1086/591033.CrossRefPubMed Zilberberg MD, Shorr AF, Kollef MH: Secular trends in candidemia-related hospitalizations in the US, 2000-2005. Infect Control Hosp Epidemiol. 2008, 29: 978-80. 10.1086/591033.CrossRefPubMed
3.
go back to reference Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the Natioanl Healthcare Safety Network at the Centes for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidmiol. 2008, 29: 996-1011. 10.1086/591861.CrossRef Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the Natioanl Healthcare Safety Network at the Centes for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidmiol. 2008, 29: 996-1011. 10.1086/591861.CrossRef
4.
go back to reference Snydman DR: Shifting patterns in the epidemiology of nosocomial Candida infections. Chest. 2003, 123: 500-503. 10.1378/chest.123.5_suppl.500S.CrossRef Snydman DR: Shifting patterns in the epidemiology of nosocomial Candida infections. Chest. 2003, 123: 500-503. 10.1378/chest.123.5_suppl.500S.CrossRef
5.
go back to reference Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996, 100: 617-23. 10.1016/S0002-9343(95)00010-0.CrossRefPubMed Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996, 100: 617-23. 10.1016/S0002-9343(95)00010-0.CrossRefPubMed
6.
go back to reference Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005, 49: 3640-5. 10.1128/AAC.49.9.3640-3645.2005.CrossRefPubMedPubMedCentral Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005, 49: 3640-5. 10.1128/AAC.49.9.3640-3645.2005.CrossRefPubMedPubMedCentral
7.
go back to reference Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis. 2006, 43: 25-31. 10.1086/504810.CrossRefPubMed Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis. 2006, 43: 25-31. 10.1086/504810.CrossRefPubMed
8.
go back to reference Labelle AJ, Micek ST, Roubinian N, Kollef MH: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008, 36: 2967-72. 10.1097/CCM.0b013e31818b3477.CrossRefPubMed Labelle AJ, Micek ST, Roubinian N, Kollef MH: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008, 36: 2967-72. 10.1097/CCM.0b013e31818b3477.CrossRefPubMed
9.
go back to reference Shorr AF, Gupta V, Sun X, Johannes RS, Spalding J, Tabak YP: Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit Care Med. 2009, 37: 2519-26. 10.1097/CCM.0b013e3181a0f95d.CrossRefPubMed Shorr AF, Gupta V, Sun X, Johannes RS, Spalding J, Tabak YP: Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit Care Med. 2009, 37: 2519-26. 10.1097/CCM.0b013e3181a0f95d.CrossRefPubMed
10.
go back to reference Smith PB, Morgan J, Benjamin JD, Fridkin SK, Sanza LT, Harrison LH, Sofair AN, Huie-White S, Benhamin DK: Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J. 2007, 26: 197-200. 10.1097/01.inf.0000253973.89097.c0.CrossRefPubMed Smith PB, Morgan J, Benjamin JD, Fridkin SK, Sanza LT, Harrison LH, Sofair AN, Huie-White S, Benhamin DK: Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J. 2007, 26: 197-200. 10.1097/01.inf.0000253973.89097.c0.CrossRefPubMed
11.
go back to reference Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005, 41: 1232-9. 10.1086/496922.CrossRefPubMed Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005, 41: 1232-9. 10.1086/496922.CrossRefPubMed
12.
go back to reference Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, León MA, EPCAN Study Group: A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006, 34: 730-7. 10.1097/01.CCM.0000202208.37364.7D.CrossRefPubMed Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, León MA, EPCAN Study Group: A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006, 34: 730-7. 10.1097/01.CCM.0000202208.37364.7D.CrossRefPubMed
13.
go back to reference Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, PAppas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH: Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007, 26: 271-6. 10.1007/s10096-007-0270-z.CrossRefPubMed Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, PAppas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH: Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007, 26: 271-6. 10.1007/s10096-007-0270-z.CrossRefPubMed
14.
go back to reference Faiz S, Neale B, Rios E, Campos T, Parsley E, Patel B, Ostrosky-Zeichner L: Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis. 2009, 28: 689-92. 10.1007/s10096-008-0666-4.CrossRefPubMed Faiz S, Neale B, Rios E, Campos T, Parsley E, Patel B, Ostrosky-Zeichner L: Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis. 2009, 28: 689-92. 10.1007/s10096-008-0666-4.CrossRefPubMed
15.
go back to reference Shorr AF, Micek ST, Jackson WL, Kollef MH: Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med. 2007, 35: 1257-62. 10.1097/01.CCM.0000261886.65063.CC.CrossRefPubMed Shorr AF, Micek ST, Jackson WL, Kollef MH: Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med. 2007, 35: 1257-62. 10.1097/01.CCM.0000261886.65063.CC.CrossRefPubMed
16.
go back to reference Micek ST, Roubinian N, Heuring T, Bode M, Williams J, Harrison C, Murphy T, Prentice D, Ruoff BE, Kollef MH: Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 2006, 34: 2707-13. 10.1097/01.CCM.0000241151.25426.D7.CrossRefPubMed Micek ST, Roubinian N, Heuring T, Bode M, Williams J, Harrison C, Murphy T, Prentice D, Ruoff BE, Kollef MH: Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 2006, 34: 2707-13. 10.1097/01.CCM.0000241151.25426.D7.CrossRefPubMed
17.
go back to reference Shorr AF, MIcek ST, Kollef MH: Inappropriate therapy for methicillin-resistant Stalhylococcus aureus: resource utilization and cost implications. Crit Care Med. 2008, 36: 2335-40. 10.1097/CCM.0b013e31818103ea.CrossRefPubMed Shorr AF, MIcek ST, Kollef MH: Inappropriate therapy for methicillin-resistant Stalhylococcus aureus: resource utilization and cost implications. Crit Care Med. 2008, 36: 2335-40. 10.1097/CCM.0b013e31818103ea.CrossRefPubMed
19.
Metadata
Title
Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study
Authors
Marya D Zilberberg
Marin H Kollef
Heather Arnold
Andrew Labelle
Scott T Micek
Smita Kothari
Andrew F Shorr
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-150

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.